Delving into the Latest Updates on HW211026 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HW211026

Target

SRC x Tubulin

Action

inhibitors

Mechanism

SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), Tubulin inhibitors

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Actinic Keratosis

Inactive Indication-

Originator Organization

Wuhan Humanwell Innovative Drug R & D Center Co., Ltd.

Active Organization

Wuhan Humanwell Innovative Drug R & D Center Co., Ltd.

Hubei Bio-Pharmaceutical Industrial Technological Institute

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价 HW211026 软膏在健康受试者中单次给药的安全性、耐受性；次要目的：1.探索 HW211026 软膏在健康受试者中单次给药的药代动力学特征，2.比较HW211026 软膏在健康受试者中大腿屈侧和面部单次给药的药代动力学和安全性，3.单次给药代谢产物的鉴定。

[Translation]

Main objective: To evaluate the safety and tolerability of a single dose of HW211026 ointment in healthy subjects; Secondary objectives: 1. To explore the pharmacokinetic characteristics of a single dose of HW211026 ointment in healthy subjects, 2. To compare the pharmacokinetics and safety of a single dose of HW211026 ointment to the thigh flexor and face in healthy subjects, 3. To identify the metabolites of a single dose.

Start Date05 Mar 2025

Sponsor / Collaborator

Wuhan Humanwell Innovative Drug R & D Center Co., Ltd.

100 Clinical Results associated with HW211026

Login to view more data

100 Translational Medicine associated with HW211026

Login to view more data

100 Patents (Medical) associated with HW211026

Login to view more data

100 Deals associated with HW211026

Login to view more data